Is Moderna Stock a Buy After Its Impressive Cancer Vaccine Results?
Moderna (NASDAQ: MRNA) delivered its biggest one-day gain in a long time on Tuesday. Its shares skyrocketed more than 20% after the company and its partner, Merck (NYSE: MRK), announced great results from a phase 2 study of experimental personalized cancer vaccine mRNA-4157/V940 combined with cancer immunotherapy Keytruda.
Even with yesterday's surge, the biotech stock remains down significantly below its highs. But is Moderna stock a buy after its impressive cancer vaccine results?
Make no mistake about it: Moderna's and Merck's results were definitely impressive. The combination of mRNA-4157/V940 and Keytruda reduced the risk of recurrence of melanoma or death by 44% versus Keytruda alone. That's huge.
Source Fool.com
